Axon Enterprise, Inc $AXON Shares Purchased by Guggenheim Capital LLC

Guggenheim Capital LLC raised its position in Axon Enterprise, Inc (NASDAQ:AXON) by 27.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 20,490 shares of the biotechnology company’s stock after buying an additional 4,352 shares during the period. Guggenheim Capital LLC’s holdings in Axon Enterprise were worth $16,964,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Banque Transatlantique SA purchased a new stake in shares of Axon Enterprise during the first quarter worth approximately $31,000. Flaharty Asset Management LLC acquired a new stake in Axon Enterprise during the 1st quarter worth $33,000. Hemington Wealth Management grew its holdings in shares of Axon Enterprise by 70.8% during the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after buying an additional 17 shares in the last quarter. Whipplewood Advisors LLC raised its position in shares of Axon Enterprise by 192.9% in the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 27 shares during the last quarter. Finally, NewSquare Capital LLC lifted its stake in shares of Axon Enterprise by 96.2% in the second quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock worth $42,000 after buying an additional 25 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Trading Up 1.3%

Shares of AXON stock opened at $550.61 on Friday. Axon Enterprise, Inc has a fifty-two week low of $469.24 and a fifty-two week high of $885.91. The company has a 50 day moving average price of $642.45 and a 200 day moving average price of $721.62. The stock has a market capitalization of $43.45 billion, a P/E ratio of 174.24, a price-to-earnings-growth ratio of 124.84 and a beta of 1.40. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The business had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. During the same quarter last year, the firm earned $1.45 EPS. The business’s revenue was up 30.6% on a year-over-year basis. Equities research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Piper Sandler cut their price objective on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Wall Street Zen lowered Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday. Barclays decreased their price target on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $870.00 price objective on shares of Axon Enterprise in a research report on Wednesday, September 24th. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $814.00.

Insiders Place Their Bets

In other news, insider Jeffrey C. Kunins sold 1,797 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $539.23, for a total transaction of $968,996.31. Following the completion of the transaction, the insider directly owned 83,485 shares of the company’s stock, valued at approximately $45,017,616.55. The trade was a 2.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jeri Williams sold 100 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total transaction of $75,254.00. Following the sale, the director owned 1,416 shares in the company, valued at $1,065,596.64. The trade was a 6.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 42,459 shares of company stock worth $28,485,977. Corporate insiders own 4.40% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.